pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Data Readout · news · pharmadog
← back to Data Readout
News · Data Readout
163
stories
9h
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
9h
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
biospace
9h
Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
biospace
1d
Ramping up: 3 biotechs growing their workforce after series C raises
biospace
2d
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
biospace
4d
Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
biospace
4d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
8d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
10d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
10d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
11d
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
biospace
11d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
11d
With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
biospace
14d
Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk
endpoints
14d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
16d
#ASH26: Kamau shares first data from revamped sickle cell gene editing therapy
endpoints
16d
Servier’s $1.6B muscular dystrophy bet on Edgewise delivers quick-fire pivotal failure
fiercebiotech
17d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
21d
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
biospace
22d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
22d
The cost of waiting: What reaching clinical proof-of-concept sooner means for biotech cash burn
fiercebiotech
23d
Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
fiercebiotech
24d
After Makary's FDA exit, biopharma exhales: Signal Survey
endpoints
25d
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
biospace
26d
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
fiercebiotech
27d
Cancer vaccine data from #ESMO26; Treasury proposal could curb China investment; and more
endpoints
28d
STAT+: Tango builds on Revolution Medicines’ pancreatic cancer success
stat
28d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
29d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
29d
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
biospace
← prev
page 1 of 6
next →